Renal Cell Carcinoma: Update on Clinical Data, Trials, and Guidance for Community Practice

Learn current and novel best-practice strategies for the management of patients with renal cell carcinoma based on biomarker assessment and clinical data in these interactive, expert led 1-hour workshops

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • Program Overview
  • Perplexities in non-metastatic RCC at Initial Diagnosis
  • Immuno-Oncology Combinations in First-Line Metastatic RCC
  • Case Examples with Discussion
    • Planning Optimal First-Line Treatment for Individual patients with Advanced or Metastatic RCC
    • Optimal Treatment for Patients with Progressive RCC after 1 or More Previous Lines of Therapy
  • Management of Adverse Events Associated with Immunotherapy-Based Combinations for Advanced RCC
  • Looking Ahead: Ongoing clinical trials
  • Closing Remarks and Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Eric Jonasch, MD

Professor, Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging therapies for treatment of RCC.

Target Audience
This interprofessional training program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with RCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Appraise clinical data on systemic treatment approaches for patients with operable, advanced or metastatic RCC
  • Identify patients most likely to benefit from targeted and/or immune checkpoint inhibitor–based combination therapies based on risk and biomarker assessment, along with patient medical and treatment history
  • Plan optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration targeted and immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preferences
  • Apply guideline-directed therapeutic strategies to optimize the sequence of therapies to provide the best outcome to patients with RCC
  • Manage specific disease-related complications or adverse events associated with currently approved monotherapies and therapy combinations for advanced RCC
  • Select patients who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category l Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-183-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.